Somryst® is the first and only prescription digital therapeutic indicated to treat chronic insomnia. Somryst is intended to improve insomnia symptoms by providing neurobehavioral intervention (cognitive behavioral therapy for insomnia – CBT-I) to adults 22 years of age and older with chronic insomnia.

Pear Therapeutics, Inc. is a venture-backed digital health company focused on the development of digital therapies and drug/software combinations to treat diseases with high unmet medical need.  PEAR's patented, clinically validated approach is designed to provide enhanced outcomes for patients, actionable data for clinicians, and cost-effective solutions for payers.

Sleepio is an online sleep improvement programme that is clinically proven to be many times more effective than sleeping pills. Co-Founded by ex-insomnia-sufferer Peter Hames and world sleep expert Professor Colin Espie, Sleepio is now on sale in Boots pharmacies across the UK.Advisors includes Martha Lane Fox (UK Digital Champion, Co-Founder of lastminute.com) and Prof Sir Neil Douglas (Chair of the Academy of Medical Royal Colleges) and investors include Esther Dyson.

Sleepio is an online sleep improvement programme that is clinically proven to be many times more effective than sleeping pills. Co-Founded by ex-insomnia-sufferer Peter Hames and world sleep expert Professor Colin Espie, Sleepio is now on sale in Boots pharmacies across the UK.Advisors includes Martha Lane Fox (UK Digital Champion, Co-Founder of lastminute.com) and Prof Sir Neil Douglas (Chair of the Academy of Medical Royal Colleges) and investors include Esther Dyson.

Somryst provides a clinician facing dashboard that allows healthcare providers to track patient treatment and progress. The clinician dashboard displays information about patients’ use of Somryst, including the Insomnia Severity Index (ISI)1, the Patient Health Questionnaire 8 (PHQ-8)2 scores, and sleep metrics derived from nightly sleep diaries.